Login
Navigate Fool.com
Will SGMO beat
the market?
Community Rating: 2 Stars: Unattractive

13.99 -0.27 (-1.89%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.26
Previous Close $14.26
Daily Range $13.74 - $14.54
52-Week Range $6.86 - $24.69
Market Cap $933.0M
P/E Ratio -29.15
Dividend (Yield) $0.00 (0.0%)
Volume 1,244,480
Average Daily Volume 1,861,992
Current FY EPS -$0.23

How do you think SGMO
will perform against the market?

Top SGMO Bull/Bear Pitches

 

TMFBiologyFool (< 20)
Submitted September 29, 2011

Good technology, but things need to be worked out. This is more of a buy and forget stock.

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 1, 2008

Sangamo. The very name brings bile to my throat and sets an artery to throbbing in my temple. Much like the name Alamo might to a Texan. I knew this company was crap. I knew zinc fingers were bull. Bu … More

0 Replies Reply Report this Post

News & Commentary Rss Feed

Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)

The market cap of Galena Biopharma, Sangamo BioSciences, and ANI Pharmaceuticals, and MannKind is more important than the share price.

First Week of SGMO April 19th Options Trading

Tuesday's ETF Movers: GDXJ, XBI

Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher

Sector Update: Healthcare Shares Flat Pre-Market; Sangamo Drops 2% on Pricing Public Offering

What You Need to Know About Sangamo Biosciences' Surge

Sangamo's (SGMO) HIV drug SB-728-T may offer a new way of battling the disease that may allow it to compete against Johnson & Johnson (JNJ) and Gilead (GILD).

This Week in Biotech: Put It in Print

Four clinical updates -- two of them in print -- as well as an FDA approval after seven years are this week's top biotech stories.

Why Sangamo Biosciences, Inc. Trounced the Market

Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.

Mid-Afternoon Market Update: Markets Turn Up From the Lows, Fuel Cell Companies Show Weakness

Why Sangamo Biosciences Inc. Shares Surged

Sangamo shares soared after it released intriguing clinical data in its attempt to treat HIV. Should shareholders be excited or cautious regarding Sangamo's move higher?

See More SGMO News...

Sector

Healthcare

Industry

Drugs

Sangamo Biosciences, Inc. (SGMO) Description

The Company deals in the research, development and commercialization of DNA-binding proteins for the therapeutic regulation and modification of disease-related genes. Website: http://www.sangamo.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks